A phase 1 study of LY4101174 (ETx-22), an antibody-drug conjugate targeting nectin-4, in patients with advanced or metastatic urothelial cancer and other solid tumors (trial in progress)

被引：0
|
作者：
Rosenberg, Jonathan
Sabatier, Renaud
Viceneux, Armelle
Rouge, Thibault De la Motte
Champiat, Stephane
Lebellec, Loic
Barthelemy, Philippe
Sonpavde, Guru
Gao, Xin
Niglio, Scot
Zhang, Tian
Gedye, Craig
Galsky, Matthew
Milowsky, Matthew
Reimers, Melissa
Weickhardt, Andrew
Grande, Enrique
Castellano, Daniel E.
Bilen, Mehmet
Patnaik, Amita
Zerbib, Robert
Balbas, Minna
Xu, Xiaojian
Aptaker, Kaitlyn
Balar, Arjun V.
Awada, Ahmad H.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT084
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT084
引用
收藏
页数：2
相关论文
共 50 条
  • [41] First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors
    Garrido-Laguna, Ignacio
    Krop, Ian
    Burris, Howard A., III
    Hamilton, Erika
    Braiteh, Fadi
    Weise, Amy M.
    Abu-Khalaf, Maysa
    Werner, Theresa L.
    Pirie-Shepherd, Steven
    Zopf, Christopher J.
    Lakshminarayanan, Mani
    Holland, Jaymes S.
    Baffa, Raffaele
    Hong, David S.
    INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (07) : 1798 - 1808
  • [42] A phase 1/2 trial of CBX-12, an alphalex™ peptide drug conjugate, in patients with advanced or metastatic refractory solid tumors
    Tolcher, Anthony
    Eder, Joseph Paul
    Sommerhalder, David
    Gayle, Sophia
    Pearson, Paul
    Chapman, Deb
    DeCillis, Arthur P.
    Thomas, Anish
    Meric-Bernstam, Funda
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [43] Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors
    Rottey, Sylvie
    Clarke, Jeffrey
    Aung, Kyaw
    Machiels, Jean-Pascal
    Markman, Ben
    Heinhuis, Kimberley M.
    Millward, Michael
    Lolkema, Martijn
    Patel, Sandip Pravin
    de Souza, Paul
    Duca, Matteo
    Curigliano, Giuseppe
    Santoro, Armando
    Koyama, Takafumi
    Brown, Michelle
    Vezina, Heather
    He, Chunsheng
    Chu, Quincy Siu-Chung
    CLINICAL CANCER RESEARCH, 2022, 28 (01) : 95 - 105
  • [44] First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors
    Strickler, John H.
    Weekes, Colin D.
    Nemunaitis, John
    Ramanathan, Ramesh K.
    Heist, Rebecca S.
    Morgensztern, Daniel
    Angevin, Eric
    Bauer, Todd M.
    Yue, Huibin
    Motwani, Monica
    Parikh, Apurvasena
    Reilly, Edward B.
    Afar, Daniel
    Naumovski, Louie
    Kelly, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (33) : 3298 - +
  • [45] A phase 1 study of ARX788, a HER2-targeting antibody-drug conjugate, in patients with metastatic HER2-positive breast cancer
    Hu, Xichun
    Zhang, Jian
    Ji, Dongmei
    Xia, Gang
    Ji, Yanping
    Xiong, Gaozhun
    Liang, Xuejun
    CANCER RESEARCH, 2020, 80 (04)
  • [46] A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody–drug conjugate, in patients with advanced or metastatic cancer
    Christian Kollmannsberger
    Carolyn D. Britten
    Anthony J. Olszanski
    Joan Andrews Walker
    Wei Zang
    Melinda D. Willard
    David B. Radtke
    Daphne L. Farrington
    Katherine M. Bell-McGuinn
    Amita Patnaik
    Investigational New Drugs, 2021, 39 : 1613 - 1623
  • [47] Phase 1 study of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) in patients (Pts) with epithelial ovarian cancer (EOC) and other FRA-positive solid tumors.
    Borghaei, Hossein
    O'Malley, David M.
    Seward, Shelly Marie
    Bauer, Todd Michael
    Perez, Raymond P.
    Oza, Amit M.
    Jeong, Woondong
    Michenzie, Mary F.
    Kirby, Maurice William
    Chandorkar, Gurudatt
    Ruiz-Soto, Rodrigo
    Birrer, Michael J.
    Moore, Kathleen N.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [48] A phase 1 study of PF-06647020, an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients with advanced solid tumors including platinum resistant ovarian cancer (OVCA)
    Sachdev, J. C.
    Maitland, M.
    Sharma, M.
    Moreno, V.
    Boni, V.
    Kummar, S.
    Gibson, B.
    Xuan, D.
    Joh, T.
    Powell, E.
    Jackson-Fisher, A.
    Damelin, M.
    Xin, X.
    Tolcher, A.
    Calvo, E.
    ANNALS OF ONCOLOGY, 2016, 27
  • [49] Cohort expansion from the phase 1 JEWEL-101 study investigating the tissue factor-targeting antibody-drug conjugate XB002 in patients with advanced solid tumors: Metastatic castration-resistant prostate cancer cohort.
    Ulahannan, Susanna Varkey
    Johnson, Melissa Lynne
    Weiss, Mia C.
    Vandross, Andrae L.
    Vidal-Cardenas, Sofia Luz
    Syed, Mustafa
    Tolcher, Anthony W.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS237 - TPS237
  • [50] Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors
    Manisha H. Shah
    Paul Lorigan
    Mary E. R. O’Brien
    Frank V. Fossella
    Kathleen N. Moore
    Shailender Bhatia
    Maurice Kirby
    Penella J. Woll
    Investigational New Drugs, 2016, 34 : 290 - 299
12345